William Daunch

Chief Technology Officer at Focal Medical, Inc.

William Daunch has extensive work experience in the field of medical devices and combination products. William currently serves as the Chief Technology Officer at Focal Medical, Inc., where they lead research and technology development for drug delivery platform technologies in oncology, gene therapy, and immunotherapy. William is also a Team Leader at RADx, a national initiative focused on innovative COVID-19 testing approaches.

In addition, William has held advisory and leadership roles at various companies, including Rilento Pharma, LLC, where they served as an Advisor, and Additive Medical Technologies, LLC, where they were the Founder and Managing Director. At their own consulting practice, William Daunch & Associates, LLC, they specialized in accelerating the design, development, and commercialization of medical devices and combination products.

Prior to these positions, William held senior leadership roles at Allergan and Ethicon, where they directed R&D projects and product development efforts in biomaterials and biosurgical adhesive and sealant medical devices. William also gained experience in chemical development and management at Closure Medical and Triangle Analytical, Inc.

With a focus on rapid prototyping, design thinking, and customer insights, William has been instrumental in identifying unmet needs and developing game-changing medical solutions. Their expertise spans various therapeutic areas, including soft tissue repair, vascular surgery, neurosurgery, orthopedics, and laparoscopic surgery.

William Daunch completed their education in a chronological order as follows: William graduated with a High School Diploma from Bedford High School in 1985, specializing in Honors College Preparatory with Chemistry. From 1986 to 1991, they pursued a Bachelor's degree in Chemistry and Biochemistry at The University of Akron, where they obtained an ACS Certified BSc. Following this, from 1991 to 1996, they continued their studies at The University of Akron and earned a PhD in Analytical Chemistry and Polymer Physics.

Links

Previous companies

TDV Capital Partners logo

Timeline

  • Chief Technology Officer

    February, 2017 - present